Inhibikase Therapeutics, INC 8-K filings
NASDAQ
Inhibikase Therapeutics is facing a $1.625 million arbitration claim for alleged breach of contract while also progressing its clinical trials and seeking additional funding.
NASDAQ
Inhibikase Therapeutics announced progress in its clinical trials, including nearing completion of enrollment for its Phase 2 trial for Parkinson's disease and advancements in its IkT-001Pro program.
NASDAQ
Inhibikase Therapeutics has amended its previous 8-K filing to disclose the compensation details for newly appointed Chief Financial Officer, Garth Lees-Rolfe, effective April 1, 2024.
NASDAQ
Inhibikase Therapeutics reports positive preliminary feedback from the FDA regarding the approval pathway for its drug candidate IkT-001Pro in blood and gastrointestinal cancers.
NASDAQ
8-K: Inhibikase Therapeutics Announces At-The-Market Offering of up to $5.66 Million in Common Stock
Inhibikase Therapeutics has entered into an agreement to sell up to $5.66 million of its common stock through an at-the-market offering.
NASDAQ
Inhibikase Therapeutics has announced the retirement of its Chief Financial Officer, Joseph Frattaroli, effective at the end of the first quarter of 2024, and the appointment of Garth Lees-Rolfe as his successor.